Sanofi (France) Discontinues Selling Authorized Generic Version of Lovenox

Sanofi SA (NYSE: SNY) said in a letter sent to customers dated Nov. 30 that it has discontinued selling the Authorized Generic version of Lovenox (Enoxaparin). "We note that Sanofi's decision to discontinue the Authorized Generic was largely expected following a federal court injunction preventing sales of Amphastar's generic Enoxaparin," said Duane Nash, an analyst at Wedbush Securities. In sum, Lovenox should be more profitable to Sanofi without an authorized generic, provided that Momenta Pharmaceuticals Inc.'s (NASDAQ: MNTA) M-Enox remains the sole third-party generic, said Nash.

Back to news